CDSimple™ AFP, CEA & PSA Chemiluminescent ELISA Kit

Background: Due to the lack of suitable biomarker to early diagnosis of gastric cancer patients for effective treatment, nowadays there are many experiment acts to use novel biomarker such as miRNAs to early diagnosis of GC. Methods: Peripheral blood specimens were collected before treatment from 113 patients with gastric cancer. The CEACAM5 and miR-335 expression were evaluated by quantitative RT-PCR. Result: CEACAM5 mRNA expression was significantly lower in patients with AGC than patients with EGC (P < .05) and miR-335 was significantly up-regulated in AGC compare to EGC (P < .05). Moreover, CEACAM5 and miR-335 expression level correlated significantly with LNM, distant metastasis, and TNM stage (P > .05). Conclusion: Our findings demonstrate a possible relationship between the deregulation of miR-335 and CEACAM5 with GC progression, also miR-335 and CEACAM5 have the potential to recognize the AGC than EGC.

Breast tumor stratification by recurrence-risk is critical for deciding patient treatment. Here an approach combining cancer pathways microarray data complemented by RNA in situ hybridization (ISH) was investigated as a means for recurrence marker discovery and visualization in pathology specimens. LncRNA andmRNA expressions in breast carcinomas with low (n = 8) vs intermediate/high (n = 10) recurrence-scores as estimated by 21-gene assay and pathology review were compared by microarray assay. Tissue microarrays were prepared from breast carcinomas (n = 20) and ductal carcinoma in situ (DCIS) specimens (n= 84 patients) with known outcomes. Thirteen RNA ISH assays were performed: lncRNAs (BBC3-1, FER3, RAD21-AS1, ZEB1-2) and mRNAs (GLO1, GLTSCR2, TGFB1, TLR2) (implicated by the microarray data); MKI67; a pooled panel of recurrence-associated proliferation markers (BIRC5, Cyclin B1, MKI67, MYBL2, STK15); a pooled panel of non-proliferation recurrence-associated markers (CEACAM5, HTF9C, NDRG1, TP53, SLC7A5); and lncRNAs H19 and HOTAIR. Seven lncRNAs and 10 mRNAs showed significantly (P <.05) altered upregulation or downregulation by microarray assay: carcinoma RNA ISH staining did not mirror these patterns. HOTAIR staining was associated with a higher breast cancer recurrence score (P = .0152); qualitatively, H19 was massively expressed in a metaplastic triple negative breast carcinoma. Among the DCIS cohort, significant associations with multiple outcome variables were noted for TGFB1 and the non-proliferation panel (P-value range:.0001 to.047); proliferation panel staining showed an association with increasing DCIS grade (P = .0269) but not with outcomes. The findings support recurrence-risk estimation by the use of multi-marker panels that are representative of diverse cellular pathways rather than over-reliance on proliferation targets. H19, HOTAIR, and TGFB1 RNA ISH show potential for selective diagnostics.